Variation in the enzyme activity of G6PD deficiencies has an impact on malaria treatment, because antimalarials such as primaquine, sulfanilamide and sulfadoxine have been observed to cause hemolysis in G6PD deficient individuals [12]. This evidence concerns the gene G6PD and malaria.